Aesica hires director from Catalent
pharmafile | February 13, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Aesica, Catalent, muir
Contract development and manufacturing organisation (CDMO) Aesica has appointed Ian Muir to the newly-created position of commercial managing director.
Muir’s responsibilities cross three of the firm’s service offerings in API manufacture, formulation development and formulated products, and he is to lead the business into new growth markets such as China and Japan.
Reporting directly to the chief executive Dr Robert Hardy, Muir will be joining the Aesica board. Business development, S&M, key account and product management across the company will report directly to Muir who will be based at its HQ in Newcastle, UK.
Muir has over 20 years’ experience in the pharma industry, his most recent role was at Catalent where he was responsible for the global provision of contract development and manufacturing services for oral dose forms.
Hardy said: “Ian brings strong commercial business knowledge and has proven experience of delivering growth and will play a pivotal role in driving further business growth for Aesica across API, formulation development and formulated products.”
Related Content
Pharma manufacturing news in brief
Bayer says it plans to invest more than €500 million to establish additional manufacturing capacity …
Pharma manufacturing news in brief
Hospira has made significant progress in restoring quality compliance at its facilities in Rocky Mount …
Aesica gets bigger in pre-filled syringes
UK contract development and manufacturing organisation Aesica is expanding production capacity for pre-filled syringes at …